BackDrugmaker AstraZeneca settles Crestor patent case
Firm says that the deal will protect its sales of the anti-cholesterol drug until 2016
Premium(A file photo of AstraZeneca headquarters in London.)
London: Anglo-Swedish pharmaceutical company AstraZeneca on Monday said it had settled a long-running patent lawsuit over its top-selling drug Crestor.
AstraZeneca said in a statement that the deal would protect its sales of the anti-cholesterol drug until 2016.
“AstraZeneca today announced that it has entered into a settlement agreement in its US patent infringement litigation against Watson Laboratories, Inc., Actavis, Inc. (formerly known as Watson Pharmaceuticals, Inc.), and EGIS Pharmaceuticals," the company said.
Crestor generated $6.25 billion of sales in 2012, down from $6.6 billion in 2011 after losing patent protection in certain regions.
AstraZeneca’s announcement comes after it last week said it was cutting 3,900 jobs—in a major restructuring of the group over the next three years.
The group currently employs about 57,000 staff worldwide.
Dow Jones Newswires contributed to this story.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
